The Expected Toxicity Rate at the Maximum Tolerated Dose in the Standard Phase I Cancer Clinical Trial Design
- 1 October 2001
- journal article
- other
- Published by Springer Science and Business Media LLC in Drug Information Journal
- Vol. 35 (4), 1189-1199
- https://doi.org/10.1177/009286150103500416
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Operating characteristics of the standard phase I clinical trial designComputational Statistics & Data Analysis, 1999
- An evaluation of phase I cancer clinical trial designsStatistics in Medicine, 1998
- Some practical improvements in the continual reassessment method for phase I studiesStatistics in Medicine, 1995
- AN EXTENSION OF THE CONTINUAL REASSESSMENT METHODS USING A PRELIMINARY UP‐AND‐DOWN DESIGN IN A DOSE FINDING STUDY IN CANCER PATIENTS, IN ORDER TO INVESTIGATE A GREATER RANGE OF DOSESStatistics in Medicine, 1995
- A comparison of two phase I trial designsStatistics in Medicine, 1994
- Practical modifications of the continual reassessment method for phase i cancer clinical trialsJournal of Biopharmaceutical Statistics, 1994
- Methods for dose finding studies in cancer clinical trials: A review and results of a monte carlo studyStatistics in Medicine, 1991